Amylin
Profil Institute hires former Amylin chief executive
November 6, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amylin, profil institute
Clinical research firm Profil Institute has appointed former Amylin chief executive Dan Bradbury to its Board of directors. “Dan Bradbury …
AstraZeneca and BMS buy Amylin for $7 billion
July 2, 2012Sales and Marketing Amylin, AstraZeneca, BMS
AstraZeneca and Bristol-Myers Squibb have struck a deal to purchase diabetes specialist Amylin in a complicated agreement worth $7 billion. …
Amylin withheld safety data, says FDA
June 27, 2012Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, FDA, lilly
The US medicines regulator says Amylin held back data relating to the safety of its diabetes drug Bydureon. The allegation …
Amylin dismisses BMS acquisition deal
March 30, 2012Manufacturing and Production, Sales and Marketing Amylin, BMS, Bydureon, diabetes, lilly
Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to reports. Shares in Amylin rose …
Amylin to pay up to $1.6 billion to sever ties with Lilly
November 8, 2011Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, R&D, lilly
Amylin will pay up to $1.6 billion to end its diabetes pact with Lilly after a difficult year for the …
Byetta approved for use with insulin
October 19, 2011Amylin, GLP-1, diabetes, lilly
The FDA has approved the use of Lilly and Amylin’s diabetes treatment Byetta as an add-on therapy to insulin glargine.The …
Takeda and Amylin stop obesity trial
August 8, 2011Research and Development, Sales and Marketing Amylin, Takeda
Takeda and Amylin have decided to halt further studies of its combination treatment for obesity, due to ‘evolving dynamics’ within …
Lilly accused of anti-competitive practices
May 17, 2011Amylin, Boehringer, diabetes, exenatide, lilly, linagliptin
Amylin Pharmaceuticals is suing Eli Lilly and Company for alleged anticompetitive activity around Lilly’s January agreement with Boehringer Ingelheim to …
Takeda obesity drug falters at phase II
March 18, 2011Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
